Entity type
Company
Filer Snapshot
Altamira Therapeutics Ltd.
CIK 0001601936. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.
Total filings
4
Latest filing
30 Apr 2025
Industry
Pharmaceutical Preparations
Filing-backed research brief
Start with the SEC data that changes for this CIK
Latest signal: SEC filing timeline only. Each card links back to the PortfolioSavvy page where the filing evidence is closest.
Latest 13F portfolio
—
No parsed 13F portfolio row yet.
Browse latest 13FLargest parsed holding
—
Populates from the latest parsed 13F information table.
Open holding13D/G large stake
—
No recent parsed 13D/G stake row for this CIK.
Browse 13D/GInsider / owner context
—
No parsed Forms 3/4/5 owner position for this CIK.
Browse insider filingsSave this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Source: SEC filing 20-F
View Source Filing
20-F filed on 30 Apr 2025 for CIK 0001601936.
- Trading symbols
- CYTOF on OTC
- Business address
- Clarendon House, 2 Church Street, Hamilton Hm 11, Bermuda, 00000
- State of incorporation
- Bermuda
- Fiscal year-end
- 31 December
- Former SEC names
- Auris Medical Holding Ltd. (to 23 Jul 2021), Auris Medical Holding AG (to 14 Mar 2019), Auris Medical AG (to 18 Apr 2014)
Filer identity
2 identity fields
SEC record
3 source fields
Filer intelligence
What SEC filings say about Altamira Therapeutics Ltd.
A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.
SEC source mix
Counts show available parsed rows, not one combined ownership total.
13F portfolio
No rows yet
Quarterly institutional portfolio holdings.
13D/G stakes
No rows yet
Beneficial ownership and large-stake disclosures.
Forms 3/4/5
No rows yet
Officer, director, and 10% owner holdings or transactions.
No parsed ownership summary yet
We still show the SEC filing timeline below. The intelligence summary will populate when parsed 13F, 13D/G, or Forms 3/4/5 data exists for this CIK.
Latest update
What changed recently for Altamira Therapeutics Ltd.
Latest financial period: Q4 2024. Open the source-backed page to inspect the fresh filing or facts context.
Update date
30 Apr 2025
Page type
Company facts
Latest period
Q4 2024
SEC-backed company facts were refreshed from filings filed on 30 Apr 2025.
Benchmark Context
Benchmark context for this company
Altamira Therapeutics Ltd. has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.
Compared with
Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.
Why this is notable
Latest financial period: Q4 2024. That gives you a fresh baseline before you compare this company with peers.
- Latest company facts filing date: 30 Apr 2025.
- Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
- Open the facts page first if you want the cleanest path to verification.
Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.
SEC filing record
CIK 0001601936 filing coverage
Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.
SEC filings
4
First seen
10 Apr 2024
Latest filing
30 Apr 2025
Entity
Company
Observed form types
20-F
20-F/A
Industry context: Pharmaceutical Preparations.
Latest Filings
Showing the latest 4 of 4 SEC filings for Altamira Therapeutics Ltd..
20-F
20-F filing
- Filing date
- 30 Apr 2025
- Reporting date
- 31 Dec 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
20-F/A
20-F/A filing
- Filing date
- 01 Jul 2024
- Reporting date
- 31 Dec 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
20-F/A
20-F/A filing
- Filing date
- 22 Apr 2024
- Reporting date
- 31 Dec 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
20-F
20-F filing
- Filing date
- 10 Apr 2024
- Reporting date
- 31 Dec 2023
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing